Tarsus (TARS) | Stock Overview & Key Data

Tarsus Pharmaceuticals Inc. | Healthcare

US$42.98

0.02%

| Tarsus Stock Comparison:

Tarsus vs Vertex Tarsus vs Regeneron Tarsus vs Amicus Therapeutics Tarsus vs Kymera Therapeutics Tarsus vs Cg Oncology Tarsus vs S&P 500 | Market

Tarsus Performance Comparison

Loading chart data...

Tarsus

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: US$42.47 High: US$43.22

on May 23, 2025

52 Week Range

Low: US$20.08 High: US$57.28

on August 5, 2024

on February 5, 2025

All-Time High: US$63.69 on December 14, 2020

Key Statistics

Market Cap i $1.8B

EPS i -2.70

P/E Ratio (TTM) i -14.02

Forward P/E i -19.99

P/B Ratio i 5.29

PEG Ratio i -19.99

Div. Yield i 0.00%

ROE i -33.98%

Beta i 0.940

Debt to Equity i 21.13

Financial Highlights

Profitability

Gross Margin i 93.35%

Operating Margin i -33.55%

Profit Margin i -44.91%

Returns and Earnings

Return on Assets (TTM) i -16.05%

Return on Equity (TTM) i -33.98%

EBITDA i $-107.8M

Net Income (TTM) i $-104.9M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Tarsus TARS	1.81B Small-cap	-1.65%	-14.04%	-5.62%	-11.05%	-22.07%	22.96%	199.79%	109.18%
Vertex VRTX	111.05B Large-cap	-0.60%	-11.46%	-9.48%	-5.57%	7.45%	-4.58%	59.29%	51.42%
Regeneron REGN	65.09B Large-cap	-1.01%	0.08%	-17.51%	-21.50%	-17.74%	-40.29%	-15.10%	-4.02%
Amicus Therapeutics FOLD	1.93B Small-cap	-3.27%	-12.39%	-33.40%	-36.01%	-33.19%	-35.61%	-21.76%	-50.16%
Kymera Therapeutics KYMR	2.00B Small-cap	-2.51%	-3.94%	-16.48%	-37.28%	-27.88%	-13.45%	95.81%	-11.40%
Cg Oncology CGON	2.00B Small-cap	0.04%	22.72%	-5.00%	-25.07%	-12.19%	-22.53%	-27.66%	-27.66%

Ownership & Short Interest

Insider Ownership i 3.23%

Institutional Ownership i 110.44%

Shares Short i 8M

Short Ratio i 12.16

Short % of Shares Outstanding i 20.45%

Average 10-Day Volume i 729K

Average 90-Day Volume i 694K

Tarsus Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Tarsus would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is TARS's 52-week high and low?

In the last 52 weeks, Tarsus reached a high of US$57.28 (on February 5, 2025) and a low of US$20.08 (on August 5, 2024).

What is the market cap and P/E ratio for TARS?

Curious about Tarsus's size and valuation? Its market capitalization stands at 1.81B. When it comes to valuation, the P/E ratio (trailing twelve months) is -14.02, and the forward P/E (looking ahead) is -19.99.

Does TARS pay dividends? If so, what's the yield?

As for dividends, Tarsus isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Tarsus's main competitors or similar companies to consider before investing?

When looking at Tarsus, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	111.05B	Healthcare	Biotechnology	-4.58%	59.29%
Regeneron REGN	65.09B	Healthcare	Biotechnology	-40.29%	-15.10%
Amicus Therapeutics FOLD	1.93B	Healthcare	Biotechnology	-35.61%	-21.76%
Kymera Therapeutics KYMR	2.00B	Healthcare	Biotechnology	-13.45%	95.81%
Cg Oncology CGON	2.00B	Healthcare	Biotechnology	-22.53%	-27.66%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Tarsus Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Tarsus's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -33.98%, the Debt to Equity ratio from the most recent quarter is 21.13, and its Gross Profit Margin stands at 93.35%.

What is the recent revenue and earnings growth for TARS?

Looking at Tarsus's growth, its revenue over the trailing twelve months (TTM) was $234M. Compared to the same quarter last year (YoY), quarterly revenue grew by 183.70%, and quarterly earnings saw a YoY growth of 183.68%.

How much of TARS stock is held by insiders and institutions?

Wondering who owns Tarsus stock? Company insiders (like executives and directors) hold about 3.23% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 110.44%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.